Arbutus Biopharma (NASDAQ: ABUS) reported Q4 EPS of ($0.17), $0.14 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $14.08 million versus the consensus estimate of $776.33 thousand.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.